Effects of chitosan supplementation versus placebo on liver fat and metabolic parameters in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disorder affecting about one-third of the global population. It encompasses a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) and may progress to fibrosis and cirrhosis. Chitosan oligosacchar...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mahsa Rouini, Hadis Alimoradi, Ali Chamani, Fatemeh Sadat Hashemi Javaheri, Mohsen Nematy, Ebrahim Falahi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2026-02-01
Edice:	Trials
Témata:	Fatty liver disease Chitosan NAFLD Hepatic steatosis
On-line přístup:	https://doi.org/10.1186/s13063-026-09504-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!